Arvind N. Dasari
The University of Texas MD Anderson Cancer Center · 471 works · 13,126 citations · h-index 46
Top works
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
- Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
- Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
- Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
- Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases
- Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
- ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
- Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes
- Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives
- Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors
- Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer
- Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
- Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
- Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
- A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014
- Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies
- Carcinoid heart disease
- Who Should Get Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemoradiation?